FARXIGA is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Dapagliflozin Propanediol.
Product ID | 0310-6205_05eedd34-9c14-4d91-b36c-b661eff3401e |
NDC | 0310-6205 |
Product Type | Human Prescription Drug |
Proprietary Name | FARXIGA |
Generic Name | Dapagliflozin |
Dosage Form | Tablet, Film Coated |
Route of Administration | ORAL |
Marketing Start Date | 2008-01-14 |
Marketing Category | NDA / NDA |
Application Number | NDA202293 |
Labeler Name | AstraZeneca Pharmaceuticals LP |
Substance Name | DAPAGLIFLOZIN PROPANEDIOL |
Active Ingredient Strength | 5 mg/1 |
Pharm Classes | Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2015-02-02 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA202293 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2015-02-02 |
Marketing Category | NDA |
Application Number | NDA202293 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2015-02-02 |
Ingredient | Strength |
---|---|
DAPAGLIFLOZIN PROPANEDIOL | 5 mg/1 |
SPL SET ID: | 72ad22ae-efe6-4cd6-a302-98aaee423d69 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0310-6205 | FARXIGA | DAPAGLIFLOZIN |
0310-6210 | FARXIGA | DAPAGLIFLOZIN |
50090-3481 | FARXIGA | DAPAGLIFLOZIN |
50090-3482 | FARXIGA | DAPAGLIFLOZIN |
55154-6932 | FARXIGA | DAPAGLIFLOZIN |
55154-6933 | FARXIGA | FARXIGA |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
FARXIGA 88639033 not registered Live/Pending |
AstraZeneca AB 2019-10-02 |
FARXIGA 86049285 4638205 Live/Registered |
Bristol-Myers Squibb Company 2013-08-27 |